Thermo Fisher Scientific Inc. (NYSE: TMO) gained momentum in pre-market trading on October 22, with shares rising 2.6% to $557.99, ahead of its third-quarter (Q3 2025) earnings announcement scheduled before the market opens today.
Analysts expect EPS of $5.50, representing a 4.2% year-over-year increase, and revenue of $10.91 billion, up 2.9% YoY. The healthcare and life sciences giant has a strong track record of exceeding earnings estimates, having outperformed EPS projections and revenue forecasts in 75% of the past eight quarters.
Recent analyst sentiment remains mixed, with 11 downward revisions to EPS versus 7 upward, while revenue projections saw nine upgrades and only three downgrades. Thermo Fisher’s diversified portfolio—including scientific instruments, specialty diagnostics, lab services, and life science solutions—continues to support its steady financial performance.
With a market capitalization of $211.48 billion, Thermo Fisher’s fundamentals remain robust. The company maintains a current ratio of 1.93, debt-to-equity ratio of 0.7, and a net margin of 15.24%, signaling financial stability. However, six insider selling transactions in the past three months and a high RSI of 67.95 suggest the stock is nearing overbought levels.
Despite mild caution from analysts, the moderate buy rating (1.9) and average target price of $564.13 indicate continued investor confidence.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
